Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: Use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 1, 2010, Pages 26-34

  Lee, Jin Kyung ^a   Marion, Tracy L ^b   Abe, Koji ^a   Lim, Changwon ^c   Pollock, Gary M ^a,b   Brouwer, Kim L R ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMLODIPINE; ATORVASTATIN; BENAZEPRIL; DRUG METABOLITE; HYDROCHLOROTHIAZIDE; TROGLITAZONE; TROGLITAZONE GLUCURONIDE; TROGLITAZONE QUINONE; TROGLITAZONE SULFATE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG METABOLISM; EXPOSURE; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL CULTURE; IN VIVO STUDY; INCUBATION TIME; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER CELL CULTURE; MALE; METABOLITE; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; RAT; SIMULATION; TANDEM MASS SPECTROMETRY;

ADULT; ANIMALS; BILE; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHROMANS; CHROMATOGRAPHY, LIQUID; COMPUTER SIMULATION; FEMALE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PPAR GAMMA; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION;

EID: 73949093271     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.156653     Document Type: Article

References (35)

1. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences, Lawrence Erlbaum, New York.
2. Enokizono J, Kusuhara H, and Sugiyama Y (2007) Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos 35:209-214.
3. Fu Y, Sheu C, Fujita T, and Foote CS (1996) Photooxidation of troglitazone, a new antidiabetic drug. Photochem Photobiol 63:615-620.
4. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, and Gasser R (2001) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167:83-98.
5. Graham DJ, Green L, Senior JR, and Nourjah P (2003) Troglitazone-induced liver failure: a case study. Am J Med 114:299-306.
6. Hamilton GA, Jolley SL, Gilbert D, Coon DJ, Barros S, and LeCluyse EL (2001) Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res 306:85-99.
7. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
8. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, and Brouwer KL (2004) Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J Pharmacol Exp Ther 311:1203-1210.
9. Honma W, Shimada M, Sasano H, Ozawa S, Miyata M, Nagata K, Ikeda T, and Yamazoe Y (2002) Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30:944-949.
10. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, and Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641.
11. Izumi T, Hosiyama K, Enomoto S, Sasahara K, and Sugiyama Y (1997) Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J Pharmacol Exp Ther 280:1392-1400.
12. Kawai K, Kawasaki-Tokui Y, Odaka T, Tsuruta F, Kazui M, Iwabuchi H, Nakamura T, Kinoshita T, Ikeda T, Yoshioka T, et al. (1997) Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 47:356-368.
13. Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E, Galchev V, Rose K, Sinz M, and Strom SC (2000) The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab Dispos 28:1192-1197.
14. LeCluyse EL, Audus KL, and Hochman JH (1994) Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol 266:C1764-C1774.
15. Liu X, Brouwer KL, Gan LS, Brouwer KR, Stieger B, Meier PJ, Audus KL, and LeCluyse EL (1998) Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration. Pharm Res 15:1533-1539.
16. Liu X, Chism JP, LeCluyse EL, Brouwer KR, and Brouwer KL (1999a) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637-644.
17. Liu X, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, and Brouwer KL (1999b) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 277:G12-G21.
18. 2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 289:1592-1599.
19. Loi CM, Alvey CW, Vassos AB, Randinitis EJ, Sedman AJ, and Koup JR (1999) Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J Clin Pharmacol 39:920-926.
20. Masubuchi Y (2006) Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 21:347-356.
21. Mingoia RT, Nabb DL, Yang CH, and Han X (2007) Primary culture of rat hepatocytes in 96-well plates: effects of extracellular matrix configuration on cytochrome P450 enzyme activity and inducibility, and its application in in vitro cytotoxicity screening. Toxicol In Vitro 21:165-173.
22. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, and Tamai I (2004) Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 32:291-294.
23. Oshio C and Phillips MJ (1981) Contractility of bile canaliculi: implications for liver function. Science 212:1041-1042.
24. Phillips MJ, Oshio C, Miyairi M, Katz H, and Smith CR (1982) A study of bile canalicular contractions in isolated hepatocytes. Hepatology 2:763-768.
25. R Development Core Team (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
26. Smith MT (2003) Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 16:679-687.
27. Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, and Brouwer KL (2006) Hepatobiliary disposition of a drug/metabolite pair: comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 318:881-889.
28. Uhal BD and Roehrig KL (1982) Effect of dietary state on hepatocyte size. Biosci Rep 2:1003-1007.
29. Watanabe N, Tsukada N, Smith CR, and Phillips MJ (1991) Motility of bile canaliculi in the living animal: implications for bile flow. J Cell Biol 113:1069-1080.
30. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
31. Watanabe Y, Nakajima M, and Yokoi T (2002) Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30:1462-1469.
32. Yabuuchi H, Tanaka K, Maeda M, Takemura M, Oka M, Ohashi R, and Tamai I (2008) Cloning of the dog bile salt export pump (BSEP; ABCB11) and functional comparison with the human and rat proteins. Biopharm Drug Dispos 29:441-448.
33. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, and Yokoi T (1999) Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260-1266.
34. Yoshigae Y, Konno K, Takasaki W, and Ikeda T (2000) Characterization of UDP-glucuronosyltransferases (UGTS) involved in the metabolism of troglitazone in rats and humans. J Toxicol Sci 25:433-441.
35. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Bridges AS, Lee K, Belinsky MG, Kruh GD, and Brouwer KL (2006) Evaluation of the role of multidrug resistanceassociated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. J Pharmacol Exp Ther 319:1485-1491.